Literature DB >> 22714262

Application of personalized medicine to solid tumors: opportunities and challenges.

Christian Ruiz1, Markus Tolnay, Lukas Bubendorf.   

Abstract

Personalised medicine is an emerging model that will revolutionise our current healthcare system. In the last decade, several genomic aberrations were discovered that are now used as predictive markers for treatment with targeted therapeutics. The technological advances in the last few years, such as the development of high resolution DNA microarrays or second generation sequencers, have led to a dramatic increase in the number of ongoing genomic profiling studies. These studies, in turn, are leading to an enormous number of detected genomic aberrations whose biological interpretation is still pending. This review will provide an overview on the current state of personalised medicine in cancer. Discussion of the use and development of the various technologies will help us to understand the opportunities and challenges that arise when novel technologies are implemented.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22714262     DOI: 10.4414/smw.2012.13587

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  6 in total

1.  Prognostic evaluation of VEGFA genotypes and haplotypes in a cohort of Brazilian women with non metastatic breast cancer.

Authors:  Hayra de Andrade Vieira-Monteiro; Daniely Regina Freitas-Alves; Marcelo Sobral-Leite; João Marcos de Azevedo Delou; Sheyla Maria Torres Goulart-Citrangulo; Camila Telles do Nascimento; Thales Nascimento E Castro; Sérgio Koifman; Jamila Alessandra Perini; Rosane Vianna-Jorge
Journal:  Cancer Biol Ther       Date:  2016-06-02       Impact factor: 4.742

2.  Nuclear T-STAR protein expression correlates with HER2 status, hormone receptor negativity and prolonged recurrence free survival in primary breast cancer and decreased cancer cell growth in vitro.

Authors:  Sandra Sernbo; Carl A K Borrebaeck; Mathias Uhlén; Karin Jirström; Sara Ek
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

3.  Genetic Effects of Vascular Endothelial Growth Factor A (VEGF-A) and Its Association with Disease Progression in Breast Cancer Population of Saudi Arabia.

Authors:  Ibrahim Altedlawi Albalawi; Rashid Mir; F M Abu Duhier
Journal:  Asian Pac J Cancer Prev       Date:  2020-01-01

4.  Functional polymorphisms in xenobiotic metabolizing enzymes and their impact on the therapy of breast cancer.

Authors:  Rosane Vianna-Jorge; Juliana Simões Festa-Vasconcellos; Sheyla Maria Torres Goulart-Citrangulo; Marcelo Sobral Leite
Journal:  Front Genet       Date:  2013-01-22       Impact factor: 4.599

5.  Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.

Authors:  Marcelo Sobral Leite; Letícia Carlos Giacomin; Diogo Nascimento Piranda; Juliana Simões Festa-Vasconcellos; Vanessa Indio-do-Brasil; Sérgio Koifman; Rodrigo Soares de Moura-Neto; Marcelo Alex de Carvalho; Rosane Vianna-Jorge
Journal:  BMC Cancer       Date:  2014-03-14       Impact factor: 4.430

6.  Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine.

Authors:  Christian Ruiz; Stefan Kustermann; Elina Pietilae; Tatjana Vlajnic; Betty Baschiera; Leila Arabi; Thomas Lorber; Martin Oeggerli; Spasenija Savic; Ellen Obermann; Thomas Singer; Sacha I Rothschild; Alfred Zippelius; Adrian B Roth; Lukas Bubendorf
Journal:  PLoS One       Date:  2016-08-22       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.